Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Pyxis Oncology Inc shares valued at $14,362 were purchased by HUMPHREY RACHEL on Apr 21 ’25. At $1.03 per share, HUMPHREY RACHEL acquired 13,896 shares.
Also, HUMPHREY RACHEL purchased 200 shares, netting a total of over 194 in proceeds.
Before that, HUMPHREY RACHEL had added 1,400 shares to its account. In a trade valued at $1,362, the Director bought Pyxis Oncology Inc shares for $0.97 each.
As published in a research note from William Blair on November 21, 2024, Pyxis Oncology Inc [PYXS] has been rated down from an Outperform to a Mkt perform. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in early November. As of August 08, 2024, Stifel has initiated its “Buy” rating for PYXS.
Analyzing PYXS Stock Performance
During the last five days, there has been a surge of approximately 1.85%. Over the course of the year, Pyxis Oncology Inc shares have dropped approximately -29.49%. Shares of the company reached a 52-week high of $1.8200 on 01/07/25 and a 52-week low of $0.8332 on 04/07/25. A 50-day SMA is recorded $1.0771, while a 200-day SMA reached $2.4129.
Support And Resistance Levels for Pyxis Oncology Inc (PYXS)
According to the 24-hour chart, there is a support level at 1.0234, which, if violated, would cause prices to drop to 0.9468. In the upper region, resistance lies at 1.1433. The next price resistance is at 1.1866. RSI (Relative Strength Index) is 55.18 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0541, which suggests the price will decrease in the coming days. Percent R is at 20.70%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
